Srx Cardio, LLC

Mpowerd Inc.

Illumination Technologies, Inc.

Smartkable, LLC

Night Angel Products, LLC

Other

Jasibo, LLC

Fostec, Inc.

Sxr Cardio, LLC

Michael Mark Muehlemann

Thomas E Barta

Jonathan William Bourne

Kyle D Monroe

Anjali Pandey

Simeon Bowers

John Salzinger

Richard A Roberts

Douglas S Hirsh

Kevin J Blair

J Donald Noble

Kevin D Sullivan

Jason Alan Snyder

Radovan Hrinda

Vesa Nevalainen

Rolf H Mueller

Jennifer Jablow

Eric T Baldwin

Robert John Catterfeld

Robert B Perry

Margaret Thompson Reece

Karim Khattab

Darryl Alexander Thomas

Solar-powered lighting devices that may be portable and/or collapsible are described. The devices may include a housing including a first wall, a second wall, and one or more side walls between the first wall and the second wall, at least one solar panel to generate solar energy, and a rechargeable battery to store the solar energy generated. The devices may include a plurality of operating modes for controlling lights within the housing, and a microprocessor for controlling the operating modes.

Portable solar-powered devices

This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunctions; thus, there is also utility for small organic compound ligands and can raise LDL levels.

Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity

This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels.

Phenylalanine small organic compounds to directly modulate PCSK9 protein activity

Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use

This invention is related to the field of PCSK9 biology and the composition and methods of use of small molecule ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small molecule compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small molecule ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small molecule ligands that can raise LDL levels.

Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands

A method of monitoring the condition of a circuit comprises establishing a known baseline signal for a type of circuit (each is somewhat different) and defining these characteristics in terms of the lead and trailing edge angular components (@ zero crossing point), the voltage (amplitude), and the period (time length) of the waveform. Ideally, the angular component of the square wave should be vertical, or at 90 degrees to x-axis. The baseline non-regular square wave that is composed of current, voltage, any harmonic thereof, or the combination of these signals which best indicate predictive measurement attributed to the type of circuit being monitored. Future wave forms indicate the rate of decay based upon the aggregated angular, amplitude, and period components of the zero-crossing points when compared to the baseline signal and/or prior waveform of the observed specific splice. The rate of decay can help determine the life expectancy of the circuit.

Method and apparatus for predicting failures in direct current circuits

Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity

This invention is related to the field of PCSK9 biology and the composition and methods of use of small molecule ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small molecule compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small molecule ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small molecule ligands that can raise LDL levels.

Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity

An illumination device may include a body having twelve sides, the body being formed by a first body portion including six sides of the twelve sides, and a second body portion including six sides of the twelve sides. The first body portion and the second body portion may be coupled to one another at a first interface and at a second interface disposed radially inward of the first interface, wherein the first interface may be positioned in a plurality of planes, and wherein the second interface may be positioned in a single plane. At least a portion of each of the twelve sides may include a transparent window. The illumination device may include a resilient cover disposed around the body.

Deployable, multi-sided illumination devices and related methods of use

Growing community of inventors

Liverpool, NY, United States of America

Michael Mark Muehlemann